ADNI 3 Clinical Core Plans

Slides:

Advertisements

Similar presentations

Department of Neurology, Mayo Clinic Arizona

Advertisements

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.

Neuropathology and Cognitive Scores Workgroup The role of vascular and Alzheimer’s Disease pathology in differential cognitive impairment among older adults.

Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Householder, MS.

AD Research Update Steven H. Ferris, PhD Friedman Professor and Director NYU Alzheimer’s Disease Center Silberstein Alzheimer’s Institute Center for Cognitive.

Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.

Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.

How Biological Factors May Affect Memory

MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.

Aging, Memory and Alzheimer’s Disease Kinga Szigeti, MD, PhD.

EPAD update José Luis Molinuevo Worldwide-ADNI Update Meeting Friday, July 17, 2015 Washington, D.C.

Mild Cognitive Impairment

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.

conflicts of interest to report.

Effects of traumatic brain injury (TBI) & post traumatic stress disorder (PTSD) on Alzheimer’s disease (AD) in Veterans using ADNI (DOD ADNI) Michael.

PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.

The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop an infrastructure that efficiently enables the undertaking of adaptive,

Alzheimer's disease 蕭尚益丁唯洋蔡欣容. Outline introductionDisease mechanismPreventConclusion.

Can we treat Alzheimers 20 years early? 郭丕鈺王家豪張琮貿.

We Treat Alzheimers 20 years early? Can. Clinical neurologist-Reisa Sperling 1. Is a clinical neurologist, a neuroimaging researcher. 2.Is a leading force.

The clinical research of early diagnosis and ultimately the treatment of Alzheimer’s disease 許一仁董冠廷詹鎮遠陳柏廷.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Mild Cognitive Impairment, Activity Participation, Functional Difficulty, and Adaptations in Functionally Vulnerable Elderly People: A Closer Look Laraine.

Orientation to Early Memory Loss. Let’s look for some answers… What is happening? What should I do? Where should I go?

Allon Therapeutics Inc. ©2010 Allon Therapeutics Inc. 1 Allon Therapeutics Inc. Corporate Overview ASENT Annual Meeting February 2010.

CHEST 2014; 145(4): 호흡기내과 R3 박세정. Cigarette smoking ㅡ the most important risk factor for COPD in the US. low value of FEV 1 : an independent predictor.

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease Mirjana Babić.

Volume 3, Issue 4, Pages (November 2017)

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73

Can We Treat Alzheimers 20 years early?

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Presenter: Dr. Patricio Chrem

Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar

The BrainHealthRegistry

COMBINATION OF CSF PROTEIN BIOMARKERS AND BDNF, IL10 AND IL6 GENOTYPES IN EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE Mirjana Babić Leko1, Matea Nikolac Perković2,

Mayo Clinic College of Medicine

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample Marie Eckerström,

Volume 2, Issue 1, Pages (January 2016)

Imaging AD Progression Amyloid Imaging Agents.

PPMI in the Medical Literature

Modifying Disease Course in Alzheimer's Disease

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Early Dementia Distinguishing AD From MCI

Reisa Sperling, Elizabeth Mormino, Keith Johnson Neuron

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

José L Molinuevo, Craig Ritchie, Miia Kivipelto

ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue

Ron Petersen & Paul Aisen

Presenter: Dr. Patricio Chrem

Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W

Ajdina Karic and Almira Bogdanic 13th November, 2018

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Argentina Arg-ADNI Ezequiel Surace, PhD.

Boston Naming Test predicts deterioration of cerebrospinal fluid biomarkers in pre-symptomatic Alzheimer’s disease Charleen Wilder, MA, Kristina Moncrieffe,

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.

ADNI 3 UPDATE MICHAEL WEINER.

European Prevention Alzheimer’s Dementia

Presentation transcript:

ADNI 3 Clinical Core Plans Paul Aisen Ron Petersen Mike Donohue Mike Weiner

The aims of the ADNI3 Clinical Core will include: Oversight of ADNI3 clinical activities, data management, tracking and quality control, recruitment and retention of participants, regulatory oversight and financial management. Characterization of the cross-sectional features and longitudinal trajectories of cognitively normal older individuals and mild cognitive impairment. Study of the relationships among clinical/demographic, cognitive, genetic, biochemical and neuroimaging features of AD from the preclinical through dementia stages. Assessment of genetic, biomarker and clinical predictors of decline. Refinement of clinical trial designs, including secondary prevention, slowing of progression in symptomatic disease, and cognitive/behavioral management.

Key hypotheses of ADNI3 Clinical Core All or almost all normal participants with brain amyloidosis will show cognitive decline compared to those without amyloidosis, and will progress to MCI. Confirmation of this hypothesis is critical to early stage trial design and regulatory support. MCI participants who are biomarker positive (amyloid and tau) will progress more rapidly than those who are negative

Other hypotheses Amyloid-related cognitive decline involves episodic memory, executive function and orientation across the spectrum of AD AD-related cognitive decline can be captured by unsupervised web-based testing Early stage AD cognitive decline predicts later functional and clinical decline Web-based registries will facilitate recruitment for ADNI (and therapeutic trials)

ADNI3 cohorts ADNI3 will carry forward roughly 300 normals (w/wo subjective concerns) and 300 MCI (EMCI+LMCI) ADNI3 will enroll modest numbers of new normal and MCI participants ADNI3 will follow MCI participants who progress to AD dementia

Possible adjustments to assessments Drop RAVLT, add FCSRT. Drop Boston Naming. Drop Clock Drawing. Add web-based cognitive testing. CFI instead of eCOG? Reaching a consensus will be challenging, but we need to begin the discussion even as we work on additional analyses.